Dexcom (DXCM) Short Interest Update
Dexcom (NASDAQ:DXCM) was the target of a significant drop in short interest in April. As of April 13th, there was short interest totalling 12,600,819 shares, a drop of 10.9% from the March 30th total of 14,147,733 shares. Currently, 14.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,326,047 shares, the days-to-cover ratio is currently 9.5 days.
DXCM opened at $74.25 on Friday. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78. The firm has a market cap of $6,493.74, a P/E ratio of -128.02 and a beta of -0.01. Dexcom has a 52 week low of $42.62 and a 52 week high of $81.91.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. The firm had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million. equities analysts predict that Dexcom will post -0.55 earnings per share for the current fiscal year.
In other news, Chairman Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $55.91, for a total value of $559,100.00. Following the completion of the transaction, the chairman now owns 484,559 shares in the company, valued at $27,091,693.69. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Richard Doubleday sold 2,581 shares of the firm’s stock in a transaction on Friday, March 23rd. The shares were sold at an average price of $68.44, for a total value of $176,643.64. Following the completion of the transaction, the executive vice president now owns 94,429 shares of the company’s stock, valued at approximately $6,462,720.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,800 shares of company stock valued at $2,402,141. Company insiders own 1.70% of the company’s stock.
Large investors have recently modified their holdings of the business. FDx Advisors Inc. boosted its stake in Dexcom by 33.3% in the 4th quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock worth $1,324,000 after buying an additional 5,764 shares during the last quarter. LMR Partners LLP acquired a new stake in Dexcom in the 4th quarter worth about $5,444,000. California Public Employees Retirement System boosted its stake in Dexcom by 3.8% in the 4th quarter. California Public Employees Retirement System now owns 134,300 shares of the medical device company’s stock worth $7,707,000 after buying an additional 4,900 shares during the last quarter. Geode Capital Management LLC boosted its stake in Dexcom by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 800,783 shares of the medical device company’s stock worth $45,956,000 after buying an additional 8,444 shares during the last quarter. Finally, American International Group Inc. acquired a new stake in Dexcom in the 4th quarter worth about $116,000.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.